Research Summary

Dr. Butowski specializes in novel therapeutic approaches to brain tumors, clinical trials, neuro-imaging, cognitive and rehabilitative neurology, medical education, and complementary therapy. His ultimate research goal is to develop novel and effective therapeutic strategies for the treatment of patients with primary brain tumors. The most direct research application is the design and conduct of phase I, II, and III clinical trials, and Dr. Butowski is a co-investigator of National Cancer Institute-supported North American Brain Tumor Consortium clinical trials. As a member of the Brain Tumor Research Center at UCSF, his research goals have expanded to include the evaluation of novel imaging techniques and molecular profiling methods that may influence the selection of patients for treatment. His research interests also include methods and/or treatments to ensure good quality of life for patients with brain tumors and methods and/or treatments that may assist patients in recovering from or coping with brain injury. The majority of his clinical activities involve the assessment and management of adult patients with brain tumors.

Research Funding

  • April 1, 2014 - March 31, 2016 - A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R21CA186140
  • April 1, 2014 - March 31, 2016 - A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R21CA186140
  • April 1, 2014 - March 31, 2016 - A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R21CA186140
  • April 1, 2014 - March 31, 2017 - A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R21CA186140

Education

Northwestern University, Evanston, IL, BA, 1991-1995, Philosophy/Religion
University of Illinois at Chicago, Chicago, IL, MD, 1995-1999
Evanston-Northwestern Hospital, Evanston, IL, Surgical Intern, 1999-2000
UCSF Department of Neurology, Resident, 2000-2003
UCSF Department of Neurological Surgery, Neuro-Oncology Fellow, 2003-2004

Selected Publications

  1. Ellingson BM, Sampson JH, Achrol AS, Aghi MK, Krystof Bankiewicz K, Wang C, Bexon M, Brem S, Brenner AJ, Chowdhary S, Floyd JR, Han SJ, Kesari S, Randazzo D, Vogelbaum MA, Vrionis FD, Zabek M, Butowski N, Coello M, Merchant N, Merchant F Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma.  View on PubMed
  2. Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, Butowski N, Clarke JL, Berger MS, Molinaro AM, Chang SM, Costello JF, Oberheim Bush NA Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.  View on PubMed
  3. Mrugala MM, Ostrom QT, Pressley SM, Taylor JW, Thomas AA, Wefel JS, Coven SL, Acquaye AA, Haynes C, Agnihotri S, Lim M, Peters KB, Sulman EP, Salcido JT, Butowski NA, Hervey-Jumper S, Mansouri A, Oliver KR, Porter AB, Nassiri F, Schiff D, Dunbar EM, Hegi ME, Armstrong TS, van den Bent MJ, Chang SM, Zadeh G, Chheda MG The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment.  View on PubMed
  4. Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.  View on PubMed
  5. Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler JS, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve DC, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow SD Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.  View on PubMed
  6. Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE, Perry A, Phillips JJ, Tihan T, Bollen AW, Pekmezci M, Butowski N, Oberheim Bush NA, Taylor JW, Chang SM, Theodosopoulos P, Aghi MK, Hervey-Jumper SL, Berger MS, Solomon DA, Clarke JL Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.  View on PubMed
  7. Ramani B, Gupta R, Wu J, Barreto J, Bollen AW, Tihan T, Mummaneni PV, Ames C, Clark A, Oberheim Bush NA, Butowski N, Phillips D, King BE, Bator SM, Treynor EC, Zherebitskiy V, Quinn PS, Walker JB, Pekmezci M, Sullivan DV, Hofmann JW, Sloan EA, M Chang S, Berger MS, Solomon DA, Perry A The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma.  View on PubMed
  8. Lucas CG, Gupta R, Doo P, Lee JC, Cadwell CR, Ramani B, Hofmann JW, Sloan EA, Kleinschmidt-DeMasters BK, Lee HS, Wood MD, Grafe M, Born D, Vogel H, Salamat S, Puccetti D, Scharnhorst D, Samuel D, Cooney T, Cham E, Jin LW, Khatib Z, Maher O, Chamyan G, Brathwaite C, Bannykh S, Mueller S, Kline CN, Banerjee A, Reddy A, Taylor JW, Clarke JL, Oberheim Bush NA, Butowski N, Gupta N, Auguste KI, Sun PP, Roland JL, Raffel C, Aghi MK, Theodosopoulos P, Chang E, Hervey-Jumper S, Phillips JJ, Pekmezci M, Bollen AW, Tihan T, Chang S, Berger MS, Perry A, Solomon DA Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.  View on PubMed
  9. Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S, Wen PY A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).  View on PubMed
  10. Morshed RA, Reihl SJ, Molinaro AM, Kakaizada S, Young JS, Schulte JD, Butowski N, Taylor J, Bush NA, Aghi MK, Berger MS, Chang S, Clarke J, Hervey-Jumper SL The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment.  View on PubMed
  11. Rodriguez-Almaraz JE, Chang S, Clarke J, Oberheim-Bush NA, Taylor J, Buerki R, Berger M, Zablotska L, Lobach I, Butowski N A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors.  View on PubMed
  12. Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Berger MS Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.  View on PubMed
  13. Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke JL, Torkildson J, Kline C, Reddy A, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni PV, Chou D, Tan L, Theodosopoulos P, McDermott M, Berger M, Raffel C, Gupta N, Sun PP, Li Y, Shah V, Cha S, Braunstein S, Raleigh DR, Samuel D, Scharnhorst D, Fata C, Guo H, Moes G, Kim JYH, Koschmann C, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Phillips JJ, Tihan T, Bollen AW, Perry A, Solomon DA Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.  View on PubMed
  14. Butowski NA, Bringas JR, Bankiewicz KS, Aghi MK Editorial. Chronic convection-enhanced delivery: the next frontier in regional drug infusion for glioblastoma.  View on PubMed
  15. Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival.  View on PubMed
  16. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.  View on PubMed
  17. Morrison MA, Hess CP, Clarke JL, Butowski N, Chang SM, Molinaro AM, Lupo JM Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors.  View on PubMed
  18. Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR Advances in multidisciplinary therapy for meningiomas.  View on PubMed
  19. Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.  View on PubMed
  20. Morshed RA, Han SJ, Hervey-Jumper SL, Pekmezci M, Troncon I, Chang SM, Butowski NA, Berger MS Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.  View on PubMed

Go to UCSF Profiles, powered by CTSI